NCT06725524View on ClinicalTrials.gov

A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma

PHASE1RecruitingINTERVENTIONAL

Enrollment

186

Participants

Timeline

Start Date

October 12, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

B-cell Non Hodgkin Lymphoma

Interventions

BIOLOGICAL

JMT601

intravenous infusion on day 1 once a week

Trial Locations (1)

Unknown

RECRUITING

Ruijin Hospital, Shanghai

All Listed Sponsors

lead

Shanghai JMT-Bio Inc.

INDUSTRY